Overview

• The Catalonia‑developed MAP‑AD blood test uses mitochondrial DNA methylation and AI to predict progression from mild cognitive impairment to Alzheimer’s, showing 84% accuracy in iScience and holding an EU IVDF conformity mark for clinical use.
• Asturias has convened a neurology working group to unify protocols for newly approved anti‑amyloid drugs, which require intravenous administration, hospital dispensing and radiological monitoring.
• The HUCA immunology laboratory is validating blood biomarkers with patient samples to accelerate diagnosis, with hospitals across the region collaborating on collection and workflow.
• Spain continues to face diagnostic delays and a growing patient population, including younger‑onset cases, with WHO‑cited estimates that 9% are under 65 and national totals around 800,000.
• Day centres, specialised residences and family associations are scaling stimulation therapies and caregiver support, while clinicians stress prevention through exercise, sensory correction and vascular risk control.